A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one

Piggybacking off of Biogen’s controversial accelerated approval for Aduhelm, new pivotal data are coming soon from three other amyloid-targeted Alzheimer’s drugs from Roche, Eli Lilly and Biogen again.